Moderna, Inc. (MRNA)

4 Things You Need to Know if You Buy Moderna Stock Today

It's been nearly five years since Moderna (MRNA -1.60%) emerged as a biotech industry disruptor, with its COVID-19 vaccine playing a landmark role in tackling the global pandemic in late 2020. Despite its generating record sales and profits through 2022, early projections of sustained demand for coronavirus vaccinations failed to materialize, leading to a sharp drop in the business.

Moderna Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?

Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.

Why Moderna Stock Has Surged 20% This Week Despite Mixed News

Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open market. The post Why Moderna Stock Has Surged 20% This Week Despite Mixed News appeared first on Investor's Business Daily.

Moderna, Inc. (MRNA) TD Cowen 45th Annual Health Care Conference

Moderna, Inc. (NASDAQ:MRNA ) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET Corporate Participants Stephen Hoge - President Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren All right, well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.

3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.

Investors looking for growth in recent times have piled into stocks in artificial intelligence and quantum computing. But these aren't the only areas that offer the potential for explosive revenue growth and stock performance.

Everest Medicines to Hold Investor Calls with Updates on mRNA Therapeutic Vaccine Programs

SHANGHAI , Feb. 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines, today announced that it will hold investor calls to discuss recent developments on its mRNA therapeutic vaccine programs. The English session of the conference call will be held at 9:00 pm on March 6, 2025 Beijing Time (8:00 am U.S. Eastern Time on March 6), and the Mandarin session of the conference call will be held at 9:00 am Beijing Time on March 7, 2025 (8:00 pm U.S. Eastern Time …

Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds

Moderna stock toppled Thursday on reports the Trump administration is considering pulling bird flu vaccine funding. The post Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds appeared first on Investor's Business Daily.

Trump administration weighs pulling funding for Moderna bird flu vaccine, Bloomberg News reports

U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird flu vaccine, Bloomberg News reported on Wednesday, citing sources.

SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate

SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials in Australia and New Zealand, with interim results expected by 2026 Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI SK bioscience will expand its vaccine portfolio and secure global competitiveness by developing mRNA vaccines SEONGNAM, South Korea , Feb. 25, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced the commencement of global Phase 1/2 clinical trials for its mRNA-based Japanese encephalitis vaccine candidate, …

Moderna to Present at Upcoming Conferences in March 2025

CAMBRIDGE, MA / ACCESS Newswire / February 25, 2025 / Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 45th Annual Health Care Conference, on Wednesday, March 5th at 9:10am ET Barclays 27th Annual Global Healthcare Conference, on Tuesday, March 11th at 1:30pm ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website. Webcast: investors.modernatx.com.

CancerVax Announces Successful Tests of its Smart mRNA Technology

Recent in-vitro lab results confirm that the Company's proprietary Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells Recent in-vitro lab results confirm that the Company's proprietary Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells

Moderna and Other Vaccine Stocks Climb After Coronavirus News From China

Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.

3 Biotech/Healthcare Names Under $10 I Am Buying Now

Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equity purchases and covered call orders. All have had some recent positive despite the action in the shares and have good longer-term prospects.

Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So.

In the dark days of the coronavirus pandemic, Moderna (MRNA 0.42%) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped to market, not only protecting hundreds of millions of people from COVID-19, but also producing gobs of revenue and healthy profits.

Moderna: A Generational Opportunity for Investors in 2025

As bad as it may look on the charts, Moderna's NASDAQ: MRNA post-COVID let-down and market reset are over. The company stock trades at rock bottom in early 2025 and presents a generational opportunity in cutting-edge biotech.

Moderna shares move higher as investors look beyond Q4 losses to pipeline potential

Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares added more than 8% during Tuesday's session as investors remained optimistic about the company's long-term strategy following mixed fourth quarter earnings. The company last week reported a wider-than-expected loss for Q4, as revenue surpassed expectations.

Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges

On Friday, Moderna Inc. MRNA reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from EPS income of $0.55 a year ago.

A lot of concern around Moderna over next year or so, says Jefferies Michael Yee

Michael Yee, Jefferies senior analyst, joins 'Closing Bell Overtime' to talk Moderna Q4 results.

Movers: Roku, Moderna, GameStop, Palo Alto

Moderna, Inc.: Working Hard But Competition Is Working Harder

MRNA's stock surged 4,211% during COVID-19 but has since plummeted to $31, reflecting a significant bubble and raising concerns about its future. Declining revenue and net income, driven by reduced COVID-19 vaccine demand and RSV market challenges, highlight MRNA's financial instability. MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and faces tough competition.

Moderna Q4 Earnings and Revenues Beat, COVID Vaccine Sales Decline

MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue guidance.

Moderna's Q4 Loss Wider Than Expected

Moderna (MRNA 2.91%), the biotech company known for its Spikevax COVID-19 vaccine, released its fourth-quarter earnings on Feb. 14. The results revealed significant financial challenges as the market for COVID vaccines shifts from government contracts to a seasonal commercial market.

Moderna (MRNA) Reports Q4 Loss, Tops Revenue Estimates

Moderna (MRNA) came out with a quarterly loss of $2.50 per share versus the Zacks Consensus Estimate of a loss of $2.69. This compares to earnings of $0.55 per share a year ago.

Moderna beats on revenue but loses more than expected as it scales down manufacturing

Moderna beat on fourth-quarter revenue but lost more than expected for the period, as the biotech company continues to slash costs and see lower demand for its Covid vaccine. It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the rapid decline of its once-booming Covid business.

Moderna's wider-than-expected loss and soft guidance weigh on battered stock

COVID-19 vaccine sales topped consensus but RSV sales remain modest

Moderna posts bigger loss than expected as vaccine maker scales down manufacturing

Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down manufacturing amid weakening demand for its COVID-19 vaccine.

Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing Reports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28) Expects 2025 revenue range of $1.5 to 2.5 billion andending cash balance of approximately $6 billion Submitted three investigational mRNA products for regulatory approval, including Moderna's next-generation COVID vaccine, RSV vaccine for high-risk adults aged 18 to 59, and flu/COVID combination vaccine CAMBRIDGE, MA / ACCESS Newswire / February 14, 2025 / …

Moderna Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Moderna, Inc. MRNA will release its fourth-quarter financial results, before the opening bell, on Friday, Feb. 14, 2025.

Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?

We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.